Saturday, Oct. 21, 9:15 - 9:30 a.m., Room 220B, South Building Platform Presentation: Epigenetic modifications of innate immunity genes impact early - stage non-small
cell lung cancer survival: An integrative analysis of epigenome and transcriptome in Caucasian population R. Zhang, Harvard T.H. Chan School of Public Health, et al
Not exact matches
April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall
survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small
cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.
The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small
cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free
survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.
The abstract title was: Attempt to Validate Drug Repositioning for Metastatic Small
Cell Lung Cancer (SCLC) Therapy Identifies Statins Associated with
Survival Benefit.?
One, in which Dr. Weiss was the senior author, highlighted the extended
survival of metastatic small
cell lung cancer (SCLC) patients who received statins.
Among patients with non-small
cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor
cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free
survival.
Among patients with advanced non-small
cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in
survival without progression of the
cancer, but not with overall
survival, according to a study in the April 9 issue of JAMA.
«We now know much more about metabolic reprogramming of cancerous tissues in human patients, particularly that the activation of pyruvate carboxylase is important to
lung cancer cell growth and survival,» said Fan, UK professor of toxicology and faculty member of the Markey Cancer Center and CESB at the University of Ken
cancer cell growth and
survival,» said Fan, UK professor of toxicology and faculty member of the Markey
Cancer Center and CESB at the University of Ken
Cancer Center and CESB at the University of Kentucky.
The
cells exhibited many functions associated with tumor progression; their presence within mouse tumors substantially accelerated
cancer growth, and in human
lung tumors, a SiglecFhigh neutrophil signature was associated with poor patient
survival.
The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles
survival in patients with non-squamous non-small
cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to...
Long - term
survival in patients with non-small
cell lung cancer and synchronous brain metastasis treated with whole - brain radiotherapy and thoracic chemoradiation.
Now, in a new study in the journal
Cancer Cell, Shaw and a team of scientists at the Salk Institute for Biological Studies found that phenformin, a derivative of the widely - used diabetes drug metformin, decreased the size of
lung tumors in mice and increased the animals»
survival.
A randomized, phase II trial showed improved progression - free
survival in small -
cell lung cancer with maintenance sunitinib vs placebo following standard chemotherapy, according to results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
DENVER — Elderly patients with stage III non-small
cell lung cancer (NSCLC) showed improved overall
survival (OS) when treated with chemoradiation (CRT) compared to definitive radiation (RT) alone.
Injections of iPSC - EPCs did not however have significant effect on tumor growth or on overall
survival, but transducing
cells with a baculovirus expressing CD40L, a member of the TNF gene family which can induce apoptosis [6, 7], and injection into the breast
cancer lung metastasis, increased levels of pro-apoptotic cytokines in
lung tissues, indicating the induction of apoptosis by CD40L carried by the EPCs (See figure).
He concluded that the improvement in progression - free
survival and potential for overall
survival benefit should lead to a phase III trial of this therapy option in small -
cell lung cancer.
The dual - drug therapy — with analogs already in use for other diseases — doubled the
survival rate of mice with
lung cancer and halted
cancer in pancreatic
cells.
DENVER — Leptomeningeal metastases (LM), a devastating complication and predictor of poor
survival in
lung cancer patients, was found to be more prevalent in non-small
cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.
With the recent announcement that a first - line immunotherapy trial for non-small
cell lung cancer (NSCLC) is positive for
survival improvement, I can see the standard of care for
lung cancer patients radically changing over the next few years.
(PHILADELPHIA)-- The most common type of
lung cancer, non-small
cell lung cancer (NSCLC), continues to be difficult to treat, with five year
survival rates of about 36 percent for stage 3A tumors.
Life tables were used to model five year
survival for early stage non-small
cell lung cancer and limited stage small
cell lung cancer, using death rates for continuing smokers and quitters obtained from this review.
The work that garnered the honor, «An analysis of the risk and benefit of neoadjuvant chemotherapy among patients undergoing surgery for non-small
cell lung cancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term sur
cancer,» examined data from more than 134,000 patients in the National
Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term sur
Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term
survival.
Whitehead Institute researchers have found that an ancient, highly conserved
cell survival factor drives expression of a specific set of genes that is strongly associated with metastasis and death in patients with breast, colon, and
lung cancers.
Life table modelling on the basis of these data estimated 33 % five year
survival in 65 year old patients with early stage non-small
cell lung cancer who continued to smoke compared with 70 % in those who quit smoking.
The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial, showed that patients who were taking two different doses of Keytruda (FDA - approved two mg / kg dose and treatment dose of 10 mg / kg given every three weeks) had longer
survival compared to those who took docetaxel, the drug widely used for non-small
cell lung cancer (NSCLC).
«The TAILOR study draws out attention to the fact that outcomes are poor in second - line treatment of non — small -
cell lung cancer, with our available treatments resulting in median progression - free survivals of two or three months,» said Benjamin Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre in Melb
cancer, with our available treatments resulting in median progression - free
survivals of two or three months,» said Benjamin Solomon, MBBS, PhD, of Peter MacCallum
Cancer Centre in Melb
Cancer Centre in Melbourne.
Neutrophil - to - Lymphocyte Ratio Predicts Overall
Survival of Advanced Non-Small
Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor
When Wayne Campbell was diagnosed with small
cell lung cancer, he was given a one in 10 chance for
survival.